Skip to main content

Table 1 Demographics, baseline data and comorbidities at time of diagnosis (mean (SD) or median and range)

From: Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis

Variable All patients Patients
with BVAS ≥ 21
Patients
with BVAS < 21
p value
n of patients 101 63 38  
Age (years) 61.4 (13) 60.2 (14) 63.3 (11) 0.237
Male/female 40/61 27/36 13/25 0.389
Time from first symptoms to diagnosis (months) 5.0 (1–36) 5.0 (1–24) 6.0 (1–36) 0.822
Hemoglobin (g%) 8.4 (1.4) 8.1 (1.3) 8.8 (1.5) 0.017
Erythrocyte sedimentation rate (mm/h) 98 (5–138) 98 (5–138) 99 (14–136) 0.762
Serum albumin (g/l) 31.3 (5.4) 30.8 (5.3) 32.0 (5.6) 0.285
CRP (mg/l) 29 (1–221) 40 (2–221) 24 (1–152) 0.054
Urinary protein excretion (mg/day) 1456 (38–8474) 1259 (38–8474) 1843 (184–7344) 0.143
Serum creatinine (umol/l) 554 (84–1904) 573 (146–1904) 428 (84–1722) 0.060
HD requirement on admission (n, %) 56 (55%) 41 (65%) 15 (40%) 0.012
BVAS 21 (11–34) 24 (21–34) 15 (11–20) <0.001
p-/c-ANCA positivity (n)* 57/36 33/29 24/7 0.024
Anti-MPO level in p-ANCA positive patients (IU/ml) 67 (6–100) 67 (6–100) 70 (11–100) 0.807
Anti-PR3 level in c-ANCA positive patients (IU/ml) 100 (32–100) 100 (50–100) 82 (32–100) 0.354
Dose of iv pulse MP** mg/kg/bw 11.7 (4.1) 12.7 (4.2) 10.1 (3.3) 0.002
Dose of iv bolus CYC*** mg/kg/bw 9.7 (1.6) 9.8 (1.6) 9.5 (1.6) 0.371
Cumulative dose of MP (mg) 11640 (3006–32334) 11238 (3006–32334) 12332 (5076–26364) 0.621
Follow-up time (days) 963 (30–3000) 843 (30–3000) 1393 (51–3000) 0.231
Organ involvement n (%)     
 Renal 101 (100) 63 (100) 38 (100) 1.000
 Respiratory tract 43 (43) 38 (60) 5 (13) <0.001
 Ear-throat-nose 39 (39) 33 (52) 6 (16) <0.001
 Musculoskeletal 55 (55) 33 (52) 22 (58) 0.590
 Skin 16 (16) 9 (14) 7 (18) 0.581
 Eyes 5 (5) 4 (6) 1 (3) 0.648
 Gastrointestinal 9 (9) 9 (14) 0 (0) 0.013
 Nervous system 17 (17) 14 (22) 3 (8) 0.062
 Cardiovascular 5 (5) 5 (8) 0 (0) 0.154
Baseline comorbidities n (%) 963 (30–3000) 843 (30–3000) 1393 (51–3000) 0.231
 History of:     
  Coronary artery disease 11 (11) 9 (14) 2 (5) 0.201
  Congestive heart failure 5 (5) 4 (6) 1 (3) 0.648
  Peripheral vascular dis. 1 (1) 1 (2) 0 (0) 1.000
  Cerebrovascular disease 11 (11) 7 (11) 4 (11) 1.000
  Chronic pulmonary dis. 16 (16) 9 (14) 7 (18) 0.581
  Peptic ulcer disease 8 (8) 6 (10) 2 (5) 0.707
  Liver disease 5 (5) 4 (6) 1 (3) 0.648
  Diabetes mellitus 8 (8) 3 (5) 5 (13) 0.149
  Malignancy 7 (7) 3 (5) 4 (11) 0.421
Number of patients with     
  0 50 30 20 0.862
  1 30 19 11  
  2 or more comorbidity scores 21 14 7  
  1. *Eight patients were ANCA negative, all of them had renal biopsy which proved the diagnosis of pauci-immune crescentic glomerulonephritis
  2. **MP – methylprednisolone, administered for 98 patients
  3. ***CYC – cyclophosphamide, administered for 95 patients
  4. Comorbidity scores were given 0 if no comorbidity, 1 if a single comorbidity, 2 if two or more comorbidities existed